Prof. Dr. Meral Beksaç

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

New England Journal of Medicine, 2024

DOI 10.1056/nejmoa2400712 PMID 38832972 238 citations (Europe PMC) Source : ORCID

Isatuximab, Plus Bortezomib, Lenalidomide, and Dexamethasone (VRd) for Newly Diagnosed Multiple Myeloma (NDMM) Transplant-ineligible Patients: Frailty Subgroup Analysis of IMROZ

Clinical Lymphoma Myeloma and Leukemia, 2024

Source : ORCID

Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis

Haematologica, 2024

DOI 10.3324/haematol.2023.284325 PMID 38299578 24 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

Haematologica, 2024

DOI 10.3324/haematol.2023.284520 PMID 38546696 2 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Phase 3 Study Results of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus VRd for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (IMROZ)

Clinical Lymphoma Myeloma and Leukemia, 2024

DOI 10.1200/jco.2024.42.16_suppl.7500 7 citations (OpenAlex) Texte intégral en libre accèsSource : ORCID

Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment

Clinical Lymphoma, Myeloma and Leukemia, 2024

DOI 10.1016/j.clml.2023.10.009 PMID 38072743 7 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients

Leukemia, 2024

DOI 10.1038/s41375-023-02105-6 PMID 38062124 17 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Real-World Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Iona-MM Second Interim Analysis

Blood, 2024

DOI 10.1182/blood-2024-200165 2 citations (OpenAlex) Texte intégral en libre accèsSource : ORCID

Results From the Randomized Phase 3 DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, Dexamethasone vs Pomalidomide Plus Bortezomib, Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma

Clinical Lymphoma Myeloma and Leukemia, 2024

DOI 10.1016/s2152-2650(24)01903-7 1 citation (OpenAlex) Source : ORCID

Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM)

Journal of Clinical Oncology, 2024

DOI 10.1200/jco.2024.42.17_suppl.lba105 13 citations (OpenAlex) Texte intégral en libre accèsSource : ORCID

Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible/not intended newly diagnosed multiple myeloma (NDMM)

Journal of Clinical Oncology, 2024

DOI 10.1200/jco.2024.42.16_suppl.7506 24 citations (OpenAlex) Texte intégral en libre accèsSource : ORCID

Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

Bone Marrow Transplantation, 2024

DOI 10.1038/s41409-024-02460-7 PMID 39533015 3 citations (Europe PMC) Source : ORCID

Stem Cell (SC) Yield and Transplant with Daratumumab ± Bortezomib, Lenalidomide and Dexamethasone in Transplant-eligible Newly Diagnosed Multiple Myeloma Patients in the Phase 3 PERSEUS Study

Clinical Lymphoma Myeloma and Leukemia, 2024

Source : ORCID

The Many Faces of Multiple Myeloma,Multipl Myelomun Farklı Yüzleri

Turkish Journal of Hematology, 2024

DOI 10.4274/tjh.galenos.2023.2023.0183 PMID 37540065 Texte intégral en libre accèsSource : ORCID

Transcriptome Analysis of Beta-Catenin-Related Genes in CD34+ Haematopoietic Stem and Progenitor Cells from Patients with AML

Mediterranean Journal of Hematology and Infectious Diseases, 2024

DOI 10.4084/mjhid.2024.058 PMID 38984092 1 citation (Europe PMC) Texte intégral en libre accèsSource : ORCID

VCd versus VRd in Newly Diagnosed Multiple Myeloma: Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG)

Clinical Lymphoma, Myeloma and Leukemia, 2024

DOI 10.1016/j.clml.2024.08.007 PMID 39304364 1 citation (Europe PMC) Source : ORCID

Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study

Blood, 2024

DOI 10.1182/blood-2024-200071 Source : ORCID

Validation of the second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma in a real-world cohort: an analysis by the Balkan myeloma study group (BMSG)

Leukemia and Lymphoma, 2024

DOI 10.1080/10428194.2024.2391900 PMID 39141607 2 citations (Europe PMC) Source : ORCID

Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Blood, 2024

DOI 10.1182/blood-2024-205608 37 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial.

Journal of Clinical Oncology, 2024

DOI 10.1200/jco.2024.42.16_suppl.7502 26 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study

Blood, 2024

DOI 10.1182/blood-2024-205077 18 citations (OpenAlex) Source : OpenAlex

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial

Blood, 2024

DOI 10.1182/blood-2024-200871 14 citations (OpenAlex) Source : OpenAlex

OA-63 Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study

Clinical Lymphoma Myeloma & Leukemia, 2024

DOI 10.1016/s2152-2650(24)02344-9 8 citations (OpenAlex) Source : OpenAlex

P-413 Characterization and Management of Ocular Events in Patients Treated With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone in the DREAMM-8 Study

Clinical Lymphoma Myeloma & Leukemia, 2024

DOI 10.1016/s2152-2650(24)02315-2 8 citations (OpenAlex) Source : OpenAlex

Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study

Blood, 2024

DOI 10.1182/blood-2024-199550 4 citations (OpenAlex) Source : OpenAlex

Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial

Blood, 2024

DOI 10.1182/blood-2024-197908 4 citations (OpenAlex) Source : OpenAlex

P-426 Isatuximab, Plus Bortezomib, Lenalidomide, and Dexamethasone (VRd) for Newly Diagnosed Multiple Myeloma (NDMM) Transplant-ineligible Patients: Frailty Subgroup Analysis of IMROZ

Clinical Lymphoma Myeloma & Leukemia, 2024

DOI 10.1016/s2152-2650(24)02347-4 3 citations (OpenAlex) Source : OpenAlex

OA-48 Daratumumab (DARA)/Bortezomib/Lenalidomide/Dexamethasone (D-VRd) With D-R Maintenance (Maint) in Transplant-eligible (TE) Newly Diagnosed Myeloma (NDMM): PERSEUS Cytogenetic Risk Analysis

Clinical Lymphoma Myeloma & Leukemia, 2024

DOI 10.1016/s2152-2650(24)01889-5 3 citations (OpenAlex) Source : OpenAlex

OA-49 Phase 3 Study Results of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus VRd for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (IMROZ)

Clinical Lymphoma Myeloma & Leukemia, 2024

DOI 10.1016/s2152-2650(24)01890-1 2 citations (OpenAlex) Source : OpenAlex

Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study

Blood, 2024

DOI 10.1182/blood-2024-207087 2 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study

Blood, 2024

DOI 10.1182/blood-2024-201057 2 citations (OpenAlex) Source : OpenAlex

OA-13 Belantamab Mafodotin, Pomalidomide, and Dexamethasone vs Pomalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Patient-Reported Outcomes from DREAMM-8

Clinical Lymphoma Myeloma & Leukemia, 2024

DOI 10.1016/s2152-2650(24)01854-8 1 citation (OpenAlex) Source : OpenAlex

PRE-TRANSPLANT DEPRESSION FOUND TO BE RELEATED TO DELAY OF NEUTROPHIL ENGRAFTMENT IN MULTIPLE MYELOMA PATIENTS WHO UNDERGO AUTOLOGOUS PERIPHERAL STEM CELL TRANSPLANTATION

2024

DOI 10.22541/au.172486331.10819573/v1 Texte intégral en libre accèsSource : OpenAlex

Germline genetic variants in Turkish familial multiple myeloma/monoclonal gammopathy of undetermined significance cases

British Journal of Haematology, 2023

DOI 10.1111/bjh.19271 PMID 38115798 4 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

A Novel Hypothesis: Certain KIR/Cognate Ligand Containing Genotypes Differ in Frequency Among Patients With Myeloma and Have an Effect on Age of Disease Onset

Clinical Lymphoma, Myeloma and Leukemia, 2023

DOI 10.1016/j.clml.2023.02.007 PMID 36918304 3 citations (Europe PMC) Source : ORCID

A Single Center Real-World Data Comparing Salvage Autologous Hematopoietic StemCell Transplantation, Selinexor Combo and Elranatamab Alone Among Triple Class Refractory Myeloma Patients: Better Efficacy with Elranatamab

Blood, 2023

DOI 10.1182/blood-2023-173644 1 citation (OpenAlex) Source : ORCID

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RELAPS/REFRACTORY LYMPHOMA PATIENTS: A SINGLE CENTER EXPERIENCE

Bone Marrow Transplantation, 2023

Source : ORCID

ALPHA-1-ANTITRYPSIN EXPERIENCE FOR STEROID-RESISTANT ACUTE GRAFT-VERSUS-HOST DISEASE

Bone Marrow Transplantation, 2023

DOI 10.1007/s12288-022-01524-2 PMID 35747565 Texte intégral en libre accèsSource : ORCID

AUTOLOGOUS PERIPHERAL BLOOD STEM CELL MOBILISATION TECHNIQUES, CELL YIELDS AND PRACTICE VARIATION-BYCOUNTRY IN MYELOMA PATIENTS UNDERGOING FIRST AUTOLOGOUS STEM CELL TRANSPLANTS IN EBMT CENTRES (2012-2021)

Bone Marrow Transplantation, 2023

Source : ORCID

Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis: A 20-year Experience in a Single Center

Balkan Medical Journal, 2023

DOI 10.4274/balkanmedj.galenos.2023.2022-2-32 PMID 36959692 1 citation (Europe PMC) Texte intégral en libre accèsSource : ORCID

Allogeneic Stem Cell Transplantation for Relapsed and/or Refractory Hodgkin Lymphoma: A Multicenter Real World Experience

Blood, 2023

DOI 10.1182/blood-2023-182741 2 citations (OpenAlex) Texte intégral en libre accèsSource : ORCID

An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT

Bone Marrow Transplantation, 2023

DOI 10.1038/s41409-023-01999-1 PMID 37160942 9 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Bortezomib-Cyclophosphamide-Dexamethasone (VCD) Vs Bortezomib-LenalidomideDexamethasone (VRD) in Newly Diagnosed Multiple Myeloma: A Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG)

Blood, 2023

DOI 10.1182/blood-2023-179416 2 citations (OpenAlex) Source : ORCID

Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT

Bone Marrow Transplantation, 2023

DOI 10.1038/s41409-023-02048-7 PMID 37543712 3 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Comparison of C-11 Methionine and F-18 FDG PET/CT findings in evaluation of Multiple Myeloma: First Turkey Experience

European Journal of Nuclear Medicine and Molecular Imaging, 2023

Source : ORCID

Cryopreserved Versus Non-Cryopreserved Peripheral Blood Haematopoietic Stem Cells for Autologous Stem Cell Transplantation in Multiple Myeloma: A Comparative Analysis from the Chronic Malignancies Working Party of EBMT and WBMT

Blood, 2023

DOI 10.1182/blood-2023-182808 Texte intégral en libre accèsSource : ORCID

EXTERNAL VALIDATION OF THREE EXISTING EARLY MYELOMA RELAPSE SCORES (BY EBMT, CIBMTR, AND GIMEMA) IN A SINGLE CENTER SHOWS MAJOR DIFFERENCES

Bone Marrow Transplantation, 2023

Source : ORCID

Efficacy and Safety of Daratumumab (DARA) Monotherapy in Patients with IntermediateRisk or High-Risk Smoldering Multiple Myeloma (SMM): Final Analysis of the Phase 2 Centaurus Study

Blood, 2023

DOI 10.1182/blood-2023-181765 8 citations (OpenAlex) Source : ORCID

Eltrombopag for the Treatment of Poor Graft Function Following Haematopoietic Cell Transplantation: Real-Life Data

Balkan Medical Journal, 2023

DOI 10.4274/balkanmedj.galenos.2022.2022-2-48 PMID 36571427 10 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

Ex vivo expansion of natural killer cells for hematological cancer immunotherapy: a systematic review and meta-analysis

Clinical and Experimental Medicine, 2023

DOI 10.1007/s10238-022-00923-z PMID 36333526 2 citations (Europe PMC) Source : ORCID